Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 731-740

  Koornneef, Annemart ^a   MacZuga, Piotr ^a,b   Van Logtenstein, Richard ^a   Borel, Florie ^a,c   Blits, Bas ^a   Ritsema, Tita ^a   Van Deventer, Sander ^b   Petry, Harald ^a   Konstantinova, Pavlina ^a  

^a Amsterdam Molecular Therapeutics ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; BETA INTERFERON; CHOLESTEROL; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADENO ASSOCIATED VIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EMBRYO; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INHIBITION KINETICS; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; MURINAE; MUS;

EID: 79953318154     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.6     Document Type: Article

References (50)

1. Rader, DJ, Cohen, J and Hobbs, HH (2003). Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111: 1795-1803. (Pubitemid 38057721)
2. Kashani, A, Phillips, CO, Foody, JM, Wang, Y, Mangalmurti, S, Ko, DT et al. (2006). Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114: 2788-2797. (Pubitemid 46018281)
3. Young, SG (1990). Recent progress in understanding apolipoprotein B. Circulation 82: 1574-1594. (Pubitemid 20367961)
4. Greeve, J, Altkemper, I, Dieterich, JH, Greten, H and Windler, E (1993). Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 34: 1367-1383. (Pubitemid 23230314)
5. Zambon, A, Brown, BG, Deeb, SS and Brunzell, JD (2006). Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med 259: 473-480.
6. Raal, FJ, Santos, RD, Blom, DJ, Marais, AD, Charng, MJ, Cromwell, WC et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375: 998-1006.
7. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
8. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
9. Grimm, D (2009). Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 61: 672-703.
10. Liu, YP, Haasnoot, J, ter Brake, O, Berkhout, B and Konstantinova, P (2008). Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 36: 2811-2824. (Pubitemid 351737175)
11. Zamore, PD, Tuschl, T, Sharp, PA and Bartel, DP (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
12. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
13. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
14. Rozema, DB, Lewis, DL, Wakefield, DH, Wong, SC, Klein, JJ, Roesch, PL et al. (2007). Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104: 12982-12987. (Pubitemid 351737577)
15. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157. (Pubitemid 47538115)
16. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
17. Manjunath, N, Wu, H, Subramanya, S and Shankar, P (2009). Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 61: 732-745.
18. Grimm, D, Pandey, K and Kay, MA (2005). Adeno-associated virus vectors for short hairpin RNA expression. Meth Enzymol 392: 381-405. (Pubitemid 40092527)
19. Daya, S and Berns, KI (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583-593.
20. Vaessen, SF, Veldman, RJ, Comijn, EM, Snapper, J, Sierts, JA, van den Oever, K et al. (2009). AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and highdensity lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency. J Gene Med 11: 697-707.
21. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
22. Kim, VN (2005). Small RNAs: classification, biogenesis, and function. Mol Cells 19: 1-15.
23. Lagos-Quintana, M, Rauhut, R, Yalcin, A, Meyer, J, Lendeckel, W and Tuschl, T (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739. (Pubitemid 34455427)
24. Elmén, J, Lindow, M, Silahtaroglu, A, Bak, M, Christensen, M, Lind-Thomsen, A et al. (2008). Antagonism of microRNA-122 in mice by systemically administered LNAantimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36: 1153-1162. (Pubitemid 351330933)
25. Jiao, S, Cole, TG, Kitchens, RT, Pfleger, B and Schonfeld, G (1990). Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. Metab Clin Exp 39: 155-160. (Pubitemid 20053274)
26. Matsuzawa, N, Takamura, T, Kurita, S, Misu, H, Ota, T, Ando, H et al. (2007). Lipidinduced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46: 1392-1403. (Pubitemid 350155521)
27. Nakai, H, Fuess, S, Storm, TA, Muramatsu, S, Nara, Y and Kay, MA (2005). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 79: 214-224. (Pubitemid 39650967)
28. Shen, X, Storm, T and Kay, MA (2007). Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol Ther 15: 1955-1962. (Pubitemid 350011735)
29. Chen, SH, Habib, G, Yang, CY, Gu, ZW, Lee, BR, Weng, SA et al. (1987). Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 238: 363-366. (Pubitemid 17151728)
30. Crooke, RM, Graham, MJ, Lemonidis, KM, Whipple, CP, Koo, S and Perera, RJ (2005). An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46: 872-884.
31. Fazio, S and Linton, MF (2001). Debate: "How low should LDL cholesterol be lowered" Viewpoint: "It doesn't need to be very low". Curr Control Trials Cardiovasc Med 2: 8-11. (Pubitemid 32219919)
32. Kastelein, JJ, Wedel, MK, Baker, BF, Su, J, Bradley, JD, Yu, RZ et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735. (Pubitemid 44607121)
33. Giering, JC, Grimm, D, Storm, TA and Kay, MA (2008). Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16: 1630-1636.
34. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873. (Pubitemid 351758464)
35. Amendola, M, Passerini, L, Pucci, F, Gentner, B, Bacchetta, R and Naldini, L (2009). Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther 17: 1039-1052.
36. Schonfeld, G, Lin, X and Yue, P (2005). Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci 62: 1372-1378. (Pubitemid 40853825)
37. Tarugi, P, Averna, M, Di Leo, E, Cefalù, AB, Noto, D, Magnolo, L et al. (2007). Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 195: e19-e27. (Pubitemid 350087974)
38. Straarup, EM, Fisker, N, Hedtjärn, M, Lindholm, MW, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38: 7100-7111.
39. Nishina, K, Unno, T, Uno, Y, Kubodera, T, Kanouchi, T, Mizusawa, H et al. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of -tocopherol. Mol Ther 16: 734-740. (Pubitemid 351426175)
40. Visser, ME, Akdim, F, Tribble, DL, Nederveen, AJ, Kwoh, TJ, Kastelein, JJ et al. (2010). Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 51: 1057-1062.
41. Kappel, S, Matthess, Y, Kaufmann, M and Strebhardt, K (2007). Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nat Protoc 2: 3257-3269.
42. Doege, H, Grimm, D, Falcon, A, Tsang, B, Storm, TA, Xu, H et al. (2008). Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem 283: 22186-22192.
43. Zuker, M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415. (Pubitemid 37442169)
44. McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P and Samulski, RJ (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118. (Pubitemid 37536760)
45. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
46. Chen, C, Ridzon, DA, Broomer, AJ, Zhou, Z, Lee, DH, Nguyen, JT et al. (2005). Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
47. Nathwani, AC, Gray, JT, Ng, CY, Zhou, J, Spence, Y, Waddington, SN et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107: 2653-2661.
48. Grimm, D, Pandey, K, Nakai, H, Storm, TA and Kay, MA (2006). Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 80: 426-439.
49. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859. (Pubitemid 34994488)
50. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985. (Pubitemid 29295202)